|Other Names||Tumor necrosis factor receptor type 1-associated DEATH domain protein, TNFR1-associated DEATH domain protein, TNFRSF1A-associated via death domain, TRADD|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||The nuclear form acts as a tumor suppressor by preventing ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A by TRIP12: acts by interacting with TRIP12, leading to disrupt interaction between TRIP12 and isoform p19ARF/ARF of CDKN2A (By similarity). Adapter molecule for TNFRSF1A/TNFR1 that specifically associates with the cytoplasmic domain of activated TNFRSF1A/TNFR1 mediating its interaction with FADD. Overexpression of TRADD leads to two major TNF-induced responses, apoptosis and activation of NF-kappa-B.|
|Cellular Location||Nucleus. Cytoplasm. Cytoplasm, cytoskeleton. Note=Shuttles between the cytoplasm and the nucleus.|
|Tissue Location||Found in all examined tissues.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The protein encoded by this gene is a death domaincontaining adaptor molecule that interacts with TNFRSF1A/TNFR1 andmediates programmed cell death signaling and NF-kappaB activation.This protein binds adaptor protein TRAF2, reduces the recruitmentof inhibitor-of-apoptosis proteins (IAPs) by TRAF2, and thussuppresses TRAF2 mediated apoptosis. This protein can also interactwith receptor TNFRSF6/FAS and adaptor protein FADD/MORT1, and isinvolved in the Fas-induced cell death pathway. [provided byRefSeq].
Pointon, J.J., et al. Ann. Rheum. Dis. 69(6):1243-1246(2010)Hosgood, H.D. III, et al. Occup Environ Med 66(12):848-853(2009)Yerges, L.M., et al. J. Bone Miner. Res. 24(12):2039-2049(2009)Liang, X.S., et al. Br. J. Haematol. 146(4):418-423(2009)Dagle, J.M., et al. Pediatrics 123(4):1116-1123(2009)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.